Reactivity profiles of broadly neutralizing anti-HIV-1 antibodies are distinct from those of pathogenic autoantibodies

AIDS

Volumn 25, Issue 10, 2011, Pages 1247-1252

  Singh, Harvir ^a   Henry, Kevin A ^b   Wu, Sampson S T ^b   Chruscinski, Andrzej ^a   Utz, Paul J ^a   Scott, Jamie K ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SIMON FRASER UNIVERSITY   (Canada)

Author keywords

AIDS vaccine; autoantibodies; autoantigen microarray; broadly neutralizing antibodies; HIV

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 4E10; NEUTRALIZING ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOREACTIVITY; MICROARRAY ANALYSIS; MILK; NONHUMAN; PRIORITY JOURNAL; SERUM; SOMATIC MUTATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; AUTOANTIBODIES; AUTOANTIGENS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 79958849986     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834785cf     Document Type: Article

References (61)

1. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009; 15:951-954.
2. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G, et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 2010; 84:1302-1313.
3. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, et al. Protection of Macaques against pathogenic simian/ human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73:4009-4018. (Pubitemid 29189846)
4. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6:207-210. (Pubitemid 30082367)
5. Breden F, Lepik C, Longo NS, Lipsky PE, Scott JK. Comparison of antibody repertoires produced by HIV-1 Infection, other chronic and acute infections, and systemic autoimmune disease. PLoS One 2011; 6:e16857.
6. Montero M, van Houten NE, Wang X, Scott JK. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev 2008; 72:54-84. (Pubitemid 351398055)
7. Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, Katinger H, et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005; 22:163-173. (Pubitemid 40255708)
8. Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, Wyatt R, et al. Structure and mechanistic analysis of the antihuman immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004; 78:10724-10737. (Pubitemid 39258398)
9. Alam SM, Morelli M, Dennison SM, Liao HX, Zhang R, Xia SM, et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci USA 2009; 106: 20234-20239.
10. Julien JP, HuarteN,MaesoR, Taneva SG, CunninghamA, Nieva JL, et al. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding. J Virol 2010; 84:4136-4147.
11. Ofek G, McKee K, Yang Y, Yang ZY, Skinner J, Guenaga FJ, et al. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J Virol 2010; 84:2955-2962.
12. Xu H, Song L, Kim M, Holmes MA, Kraft Z, Sellhorn G, et al. Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity. J Virol 2010; 84:1076-1088.
13. Zwick MB, Komori HK, Stanfield RL, Church S, Wang M, Parren PW, et al. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing antihuman immunodeficiency virus type 1 antibody 2F5. J Virol 2004; 78:3155-3161. (Pubitemid 38314375)
14. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005; 308: 1906-1908. (Pubitemid 40941873)
15. Alam SM, McAdams M, Boren D, Rak M, Scearce RM, Gao F, et al. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol 2007; 178:4424-4435. (Pubitemid 46492394)
16. Beck Z, Karasavvas N, Tong J, Matyas GR, Rao M, Alving CR. Calcium modulation of monoclonal antibody binding to phos-phatidylinositol phosphate. Biochem Biophys Res Commun 2007; 354:747-751. (Pubitemid 46186248)
17. Matyas GR, Beck Z, Karasavvas N, Alving CR. Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim Biophys Acta 2009; 1788:660-665.
18. Matyas GR, Wieczorek L, Beck Z, Ochsenbauer-Jambor C, Kappes JC, Michael NL, et al. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. AIDS 2009; 23:2069-2077.
19. Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum Antibodies 2005; 14:59-67.
20. Nabel GJ. Immunology. Close to the edge: neutralizing the HIV-1 envelope. Science 2005; 308:1878-1879. (Pubitemid 40941863)
21. Vcelar B, Stiegler G, Wolf HM, Muntean W, Leschnik B, Mehandru S, et al. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS 2007; 21:2161-2170. (Pubitemid 350287213)
22. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science 2003; 301:1374-1377. (Pubitemid 37075812)
23. Verkoczy L, Diaz M, Holl TM, Ouyang YB, Bouton-Verville H, Alam SM, et al. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci USA 2010; 107:181-186.
24. Schibli DJ, Montelaro RC, Vogel HJ. The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well defined helix in dodecylphosphocholine micelles. Biochemistry 2001; 40:9570-9578. (Pubitemid 32757895)
25. Sun ZY, Oh KJ, Kim M, Yu J, Brusic V, Song L, et al. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 2008; 28:52-63.
26. Song L, Sun ZY, Coleman KE, Zwick MB, Gach JS, Wang JH, et al. Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface. Proc Natl Acad Sci USA 2009; 106:9057-9062.
27. Dennison SM, Stewart SM, Stempel KC, Liao HX, Haynes BF, Alam SM. Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions. J Virol 2009; 83:10211-10223.
28. Xiao X, Chen W, Feng Y, Dimitrov D. Maturation pathways of cross-reactive HIV-1 neutralizing antibodies. Viruses 2009; 1:802-817.
29. Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, Wibmer CK, et al. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol 2009; 83:8925-8937.
30. Petrovas C, Vlachoyiannopoulos PG, Kordossis T, Moutsopou-los HM. Antiphospholipid antibodies in HIV infection and SLE with or without antiphospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI. J Autoimmun 1999; 13:347-355.
31. Abuaf N, Laperche S, Rajoely B, Carsique R, Deschamps A, Rouquette AM, et al. Autoantibodies to phospholipids and to the coagulation proteins in AIDS. Thromb Haemost 1997; 77:856-861. (Pubitemid 27239104)
32. Loizou S, Singh S, Wypkema E, Asherson RA. Anticardiolipin, antibeta(2)-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease. Ann Rheum Dis 2003; 62:1106-1111. (Pubitemid 37323577)
33. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11:615-622. (Pubitemid 40868301)
34. Maeso R, Huarte N, Julien JP, Kunert R, Pai EF, Nieva JL. Interaction of anti-HIV type 1 antibody 2F5 with Phospholipid bilayers and its relevance for the mechanism of virus neutralization. AIDS Res Hum Retroviruses 2011.
35. van Houten NE, Henry KA, Smith GP, Scott JK. Engineering filamentous phage carriers to improve focusing of antibody responses against peptides. Vaccine 2010; 28:2174-2185.
36. Zhu M, Olee T, Le DT, Roubey RA, Hahn BH, Woods VL Jr, et al. Characterization of IgG monoclonal anticardiolipin/anti-beta2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies. Br J Haematol 1999; 105:102-109. (Pubitemid 29197150)
37. Scherer EM, ZwickMB, TeytonL,Burton DR. Difficultiesinelicit-ing broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS 2007; 21:2131-2139. (Pubitemid 350287210)
38. Bahr SL. Peptide markers for the HIV-1 neutralizing antibody 4E10 [M.Sc. thesis]. Burnaby: Simon Fraser University; 2004.
39. Menendez A, Chow KC, Pan OC, Scott JK. Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope. J Mol Biol 2004; 338:311-327. (Pubitemid 38447088)
40. Visvanathan S, Scott JK, Hwang KK, Banares M, Grossman JM, Merrill JT, et al. Identification and characterization of a peptide mimetic that may detect a species of disease-associated antic-ardiolipin antibodies in patients with the antiphospholipid syndrome. Arthritis Rheum 2003; 48:737-745. (Pubitemid 36302011)
41. Robinson WH, DiGennaro C, HueberW, Haab BB, Kamachi M, Dean EJ, et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med 2002; 8:295-301. (Pubitemid 34250109)
42. Olee T, Pierangeli SS, Handley HH, Le DT, Wei X, Lai CJ, et al. A monoclonal IgG anticardiolipin antibody from a patient with the antiphospholipid syndrome is thrombogenic in mice. Proc Natl Acad Sci USA 1996; 93:8606-8611. (Pubitemid 26269607)
43. Garren H, Robinson WH, Krasulova E, Havrdova E, Nadj C, Selmaj K, et al. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol 2008; 63:611-620.
44. Hueber W, Kidd BA, Tomooka BH, Lee BJ, Bruce B, Fries JF, et al. Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum 2005; 52:2645-2655. (Pubitemid 41369092)
45. Richez C, Yasuda K, Bonegio RG, Watkins AA, Aprahamian T, Busto P, et al. IFN regulatory factor 5 is required for disease development in the FcgammaRIIBS/SYaa and FcgammaR-IIBS/S mouse models of systemic lupus erythematosus. J Immunol 2010; 184:796-806.
46. Robinson WH, Fontoura P, Lee BJ, de Vegvar HE, Tom J, Pedotti R, et al. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol 2003; 21:1033-1039. (Pubitemid 37064732)
47. Sekine H, Graham KL, Zhao S, Elliott MK, Ruiz P, Utz PJ, et al. Role of MHC-linked genes in autoantigen selection and renal disease in a murine model of systemic lupus erythematosus. J Immunol 2006; 177:7423-7434. (Pubitemid 44715113)
48. Thibault DL, Chu AD, Graham KL, Balboni I, Lee LY, Kohlmoos C, et al. IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice. J Clin Invest 2008; 118:1417-1426. (Pubitemid 351500435)
49. Thibault DL, Graham KL, Lee LY, Balboni I, Hertzog PJ, Utz PJ. Type I interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus. Arthritis Res Ther 2009; 11:R112.
50. Montero M. Antigenicity and immunogenicity of the membrane proximal external region of the HIV-1 envelope protein gp41 [Ph.D. thesis]. Burnaby: Simon Fraser University; 2007.
51. Brunel FM, Zwick MB, Cardoso RM, Nelson JD, Wilson IA, Burton DR, et al. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J Virol 2006; 80:1680-1687. (Pubitemid 43228710)
52. Tusher VG, Tibshirani R, Chu G. Significance analysis of micro-arrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98:5116-5121. (Pubitemid 32397092)
53. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95:14863-14868. (Pubitemid 29003722)
54. Tiller T, Tsuiji M, Yurasov S, Velinzon K, Nussenzweig MC, Wardemann H. Autoreactivity in human IgGR memory B cells. Immunity 2007; 26:205-213. (Pubitemid 46329436)
55. Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, Shukair S, et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010; 467: 591-595.
56. Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 2008; 329:112-124. (Pubitemid 350235462)
57. Guo W, Smith D, Aviszus K, Detanico T, Heiser RA, Wysocki LJ. Somatic hypermutation as a generator of antinuclear antibodies in a murine model of systemic autoimmunity. J Exp Med 2010; 207:2225-2237.
58. Heltemes-Harris L, Liu X, Manser T. An antibody VH gene that promotes marginal zone B cell development and heavy chain allelic exclusion. Int Immunol 2005; 17:1447-1461. (Pubitemid 41631321)
59. Doria-Rose NA, Klein RM, Daniels MG, O'Dell S, Nason M, Lapedes A, et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol 2010; 84:1631-1636.
60. Piantadosi A, Panteleeff D, Blish CA, Baeten JM, Jaoko W, McClelland RS, et al. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol 2009; 83:10269-10274.
61. Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 2006; 6:231-243. (Pubitemid 43290992)